Clinical Trials at Saint Peter's University Hospital

Open for Accrual

BREAST:

RTOG 0413/NSABP B-39:
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, II Breast Cancer.

PI: Alexander Haas, M.D.

ECOG E5103:
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive High Risk Lymph Node Negative Breast Cancer.

PI: Edward Licitra, M.D. Ph.D.

NSABP B-42:
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormonal Receptor Positive Breast Cancer.

PI: Kathleen Toomey, M.D.

CINJOG 040504:
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate versus Gemcitabine Alone in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

PI: Kathleen Toomey, M.D.

Study #06:62:
A Single-Site Prospective, Non-Randomized Study of the MammoSite Radiation Therapy Delivery System (Breast Brachytherapy Applicator) to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities.

PI: Gopal Desai, M.D.

CTSU - PACCT-1:
Program for the Assessment of Clinical Cancer Tests
Trial Assigning Individualized Options for Treatment: The TAILORx Trial.

PI: Craig Lampert, M.D.

S0500:
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment.

PI: Kathleen Toomey, M.D.

ECOG E1105:
A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients with HER-2/Neu Over-Expressing Metastatic Breast Cancer.

PI: Kathleen Toomey, M.D.

BRAIN:

RTOG R0614:
A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy.

PI: Gopal Desai, M.D.

GASTROINTESTINAL:

CINJ ONCOLOGY GROUP #070501
Phase II Study of Imatinib Mesylate and Gemcitabine for the First-Line Treatment of Metastatic Pancreatic Cancer.

PI: Kathleen Toomey, M.D.

CTSU E5202:
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.

PI: Craig Lampert, M.D.

ECOG E5204:
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-FU, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation.

PI: Gopal Desai, M.D.

HEAD AND NECK:

LORHAN:
Head and Neck Carcinoma Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma.

PI: Gopal Desai, M.D.

RTOG 0522:
A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin vs. Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Neck Carcinomas.

PI: Alexander Haas, M.D.

RTOG-0615:
A Phase II Study of Concurrent Chemoradiotherapy Using 3D Radiotherapy (CD-CRT) or IMRT + Bevacizumab for Locally or Regionally Advanced Nasopharyngeal Cancer.

PI: Alexander Haas, M.D.

RTG 0514:
Establishment of a Head and Neck Cancer Tissue/Specimen Bank.

PI: Gopal Desai, M.D.

GENITOURINARY:

ECOG E2805:
A Randomized Double-blind Phase III Trial of Adjuvant Sunitinib Versus Sorafenib Versus Placebo in Patients with Resected Renal Cell Carcinoma.

PI: Sameer Desai, M.D.

RTOG-0521:
Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized High-Risk Prostate Cancer.

PI: Alexander Haas, M.D.

LUNG:

CTSU SO424:
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Nonsmoking Women and Men (Smoking Arm Closed).

PI: Gopal Desai, M.D.

GYNECOLOGICAL:

CINJ ONCOLOGY GROUP #100101
A Phase II Trial of Chemosensitization with Paclitaxel, 13-cis Retoinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma.

PI: Kathleen Toomey, M.D.

RTOG 0418:
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Postoperative Patients with Either Endometrial or Cervical Carcinoma (Endometrial study closed).

PI: Alexander Haas, M.D.

MISCELLANEOUS:

07:12 NOPR
The National Pet Registry

Registry/PI: Gopal Desai, M.D.

Please call or e-mail either
Susan Maney at SPUH
732-745-8600 Ext. 8295
smaney@saintpetersuh.com
OR
Kathy Covert, APN
732-745-8600 Ext. 6163
kcovert@saintpetersuh.com

CONTACT LIST

Gopal Desai, M.D.
Chairman, Radiation Oncology
Telephone: (732) 745-8590

Alexander Haas, M.D.
Director, Radiation Oncology
Telephone: (732) 745-8590

Kathleen Toomey, M.D.
Medical Oncology
Telephone: (908) 927-8700

Craig Lampert, M.D.
Medical Oncology
Telephone: (732) 246-4882

Edward Licitra, M.D., Ph.D.
Medical Oncology
(732) 828-9570

Kathy Covert, APN, MSN, AOCN
Oncology Research Nurse
Telephone: (732) 745-8600 ext. 6163
Beeper: (732) 651-3970

Susan Maney
Oncology Research Coordinator
Telephone: (732) 745-8600 ext. 8295
Contact Information

Cancer Care:
(732) 745-8600 x8325

Gynecology/Radiation Oncology:
(732) 745-8600 x8353

Head and Neck Oncology:
(732) 745-8600 x8353

Institute for Genetic Medicine:
(732) 745-6659

Lymphedema Management:
(732) 745-8570

Outpatient Infusion:
(732) 745-8600 x5760

Pediatric Cancer Care:
(732) 745-6674

Radiation Therapy:
(732) 745-8590

Women's Imaging Center:
(732) 745-6686